Pratima Harigunani

PUNE: Oncology lab test expert OncQuest is working on new technology platforms that are currently in the preliminary stages of its R&D pipeline.

It is targeting the areas of colon and breast cancer and is developing tests for genetic predisposition in this space.

“It would be premature to reveal much about these new technology platforms. We are doing validation tests that can be extrapolated. This would address the medical needs for the segment of a complete healthy woman,” said Vivek Trikha, head of Diagnostics at OncQuest.

These development efforts would be supported by an expanded geographical presence as the company aims to increase its count of collection centers from 30 to 45 by this fiscal. International centers in South East Asia, Middle East, UK and Europe would complete the expansion script for OncQuest. This would be in addition to its existing international centers in Kathmandu and Colombo. Its research epicenter in Delhi may also be extended soon to another laboratory that might come up in Bangalore. The company, which is part of the Dabur group, currently has offerings in areas like Polymerase Chain Reaction (PCR), real time PCR, Fluorescent – In – Situ – Hybridization (FISH), Cytogenetics, flow Cytometry, immunohistochemistry and routine surgical pathology.

Trikha pegs the market size to be small but sees enormous appetite at the growth rate of 20 per cent in India.

© CyberMedia News